Lee M. Nadler

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses.

CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.

HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.

cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression.

From genomics to cancer vaccines: patient-tailored or universal vaccines?

MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.

Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.

Autoantibodies frequently detected in patients with aplastic anemia.

IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.

Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.

pH-triggered microparticles for peptide vaccination.

Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation.

Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia.

Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients.

Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.

CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.

Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival.

Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.

Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

Lee Marshall Nadler, MD: a conversation with the editor.

Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells.

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.

Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.

Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.

Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.

Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.

Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

IL-21 Can Supplement Suboptimal Lck-Independent MAPK Activation in a STAT-3-Dependent Manner in Human CD8+ T Cells.

Ex vivo expansion of human CD8 T cells using autologous CD4 T cell help.